How to appeal a Blue Cross NC copd severe + alpha-1 antitrypsin deficiency denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Blue Cross NC-specific note: BCBS licensee for North Carolina (~4.3M members). Prime Therapeutics PBM. NC DOI oversight. Blue Premier is the high-profile value-based care program. Recently divested some Medicaid business; Healthy Blue (joint venture with Elevance) handles NC Medicaid.

What Blue Cross NC's policy requires for copd severe + alpha-1 antitrypsin deficiency

Cited policy: BCBS Specialty Pharmacy — AAT Augmentation (Prolastin-C / Glassia / Aralast NP / Zemaira)

Documented severe AAT deficiency (serum <11 micromol/L AND/OR PI*ZZ, PI*SZ, or other deficient genotype) + emphysema on HRCT or PFT + non-smoker or former smoker >=6 months. 60 mg/kg IV weekly.

How Blue Cross NC denies copd severe + alpha-1 antitrypsin deficiency — and how to counter it

Where Blue Cross NC pushes back: 1) No proven mortality benefit; 2) Need to demonstrate progression first; 3) Active or recent smoking; 4) Genotype not confirmed.

Counter-arguments that hold up: RAPID + RAPID-OLE Lancet 2015 — slowed CT-density lung loss = disease modification. ATS/ERS 2003 + Alpha-1 Foundation 2024 endorse augmentation for severe deficiency + emphysema. Mortality RCT impractical given orphan population — registry data shows benefit. Submit genotype confirmation (PI*ZZ) + serum AAT <11 micromol/L + HRCT showing lower-lobe panlobular emphysema + smoking cessation date >=6 months ago.

What Blue Cross NC typically denies for copd severe + alpha-1 antitrypsin deficiency

Across Blue Cross NC's commercial and Medicare books, denials cluster around a small number of patterns. For copd severe + alpha-1 antitrypsin deficiency, expect:

• Step therapy via Prime Therapeutics
• Blue Premier value-based arrangement disputes
• Out-of-network reductions
• Specialty drug PA

Treatments most often denied in this category

These are the copd severe + alpha-1 antitrypsin deficiency treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Dupixent (eos COPD)
• Ohtuvayre
• Trelegy
• Breztri
• Open triple
• Roflumilast

How to submit the appeal to Blue Cross NC

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Blue Cross NC cited in the denial.
3. File the appeal through Blue Cross NC's portal (members: https://www.bluecrossnc.com ; providers: https://www.bluecrossnc.com/providers). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In NC, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Blue Cross NC's prior-authorization criteria by drug: Blue Cross NC PA criteria on ApprovalHelp.